RYTM ▼ -0.0% - Rhythm Pharmaceuticals, Inc. $RYTM - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity Rhythm Pharmaceuticals announced Health Canada approval of IMCIVREE for weight management in acquired hypothalamic obesity across adult and pediatric patients ages 4 and older, expanding the drug's market reach in Canada. The stock showed no net movement today despite the regulatory milestone. 22-SEP-2026 08:01 AM ET